Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 639 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transfusions Clear all
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
16
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

NCT03347396
View directory record Official record
Conditions
Agglutinin Disease, Cold
Interventions
BIVV009
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Whittier, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

NCT01035229
View directory record Official record
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients

NCT00751322
View directory record Official record
Conditions
Pulmonary Edemas, Blood Protein Disorders
Interventions
RBC transfusion of 5 days or less storage age, RBC transfusion of conventional storage age
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 8, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn No phase listed Observational

Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome

NCT04969367
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Medical Device Usage and Evaluation, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn Not applicable Interventional

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

NCT05121493
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 8, 2026, 10:59 PM EDT
Recruiting No phase listed Observational

Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome

NCT05008744
View directory record Official record
Conditions
Twin to Twin Transfusion as Antepartum Condition, Monochorionic Diamniotic Placenta
Interventions
Fetoscopic laser ablation
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

NCT00901199
View directory record Official record
Conditions
Thalassemia, Iron Overload
Interventions
Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
Drug
Lead sponsor
Elliott Vichinsky
Other
Eligibility
8 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn Phase 4 Interventional

Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty

NCT02926651
View directory record Official record
Conditions
Anemia, Arthritis, Total Knee Arthroplasty, Total Hip Arthroplasty
Interventions
Conventional Oral TXA (Tranexamic Acid), Multi-Dose Oral TXA (Tranexamic Acid)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn Phase 2 Interventional

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01251172
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Gamma-Secretase Inhibitor RO4929097, Hematopoietic Stem Cell Mobilization, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

NCT01072370
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Cord Blood Infusion, Intravenous Sham
Biological
Lead sponsor
Augusta University
Other
Eligibility
1 Year to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 8, 2026, 10:59 PM EDT
Suspended Not applicable Interventional

Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

NCT04137692
View directory record Official record
Conditions
Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1
Interventions
Red Blood Cell Transfusion
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
16 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Phase 4 Interventional

Tranexamic Acid in Revision Total Joint Arthroplasty

NCT02877381
View directory record Official record
Conditions
Revision Total Knee Arthroplasty, Revision Total Hip Arthroplasty, Acute Blood Loss Anemia
Interventions
Revision Total Knee Arthroplasty (TKA), Revision Total Hip Arthroplasty (THA)
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 8, 2026, 10:59 PM EDT
Completed No phase listed Observational Results available

Assessment of Pain in People With Thalassemia

NCT00872339
View directory record Official record
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
12 Years to 90 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Oakland, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Sep 8, 2026, 10:59 PM EDT
Active, not recruiting Not applicable Interventional

Brain Oxygen Optimization in Severe TBI, Phase 3

NCT03754114
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
ICP + PbtO2 guided management strategy, ICP guided management strategy
Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Years and older
Enrollment
1,094 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
48
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 8, 2026, 10:59 PM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT02887820
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 8, 2026, 10:59 PM EDT
Withdrawn Not applicable Interventional

Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation

NCT06022510
View directory record Official record
Conditions
Twin Monochorionic Diamniotic Placenta
Interventions
Fetoscopy Sets for Anterior and Posterior Placentas
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 8, 2026, 10:59 PM EDT
Terminated Not applicable Interventional

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276
View directory record Official record
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 8, 2026, 10:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood

NCT02607150
View directory record Official record
Conditions
Idiopathic Scoliosis, Transfusion Reaction
Interventions
Cerebral Oxygenation Changes
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 8, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Transfusion Reduction - QI Project

NCT04823273
View directory record Official record
Conditions
Blood Transfusion
Interventions
General improvement, In-line help text, Interruptive alert
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
1,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 8, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

NCT03381833
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
LJPC-401
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
14 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 8, 2026, 10:59 PM EDT